alpha thalassemia

alpha thalassemia
Name	Alpha thalassemia
Synonyms	α-thalassemia
Field	Hematology, Medical genetics
Symptoms	Anemia, fatigue, jaundice, splenomegaly
Complications	Hydrops fetalis, Iron overload, Osteoporosis
Onset	Birth or early childhood
Duration	Lifelong
Types	Silent carrier, alpha thalassemia trait, HbH disease, Hb Bart's hydrops fetalis
Causes	Mutations in the HBA1 and HBA2 genes
Risks	Family history, ancestry from Southeast Asia, the Mediterranean Basin, Middle East, Africa
Diagnosis	Complete blood count, Hemoglobin electrophoresis, Genetic testing
Treatment	Blood transfusion, Folic acid, Chelation therapy, Stem cell transplantation
Prognosis	Varies from asymptomatic to fatal
Frequency	Common in malaria-endemic regions

alpha thalassemia. It is a form of inherited blood disorder characterized by reduced synthesis of the alpha-globin chains that form part of the hemoglobin molecule. The condition results from deletions or mutations in the HBA1 and HBA2 genes located on Chromosome 16. Clinical severity ranges from a silent carrier state with no symptoms to a fatal form causing severe anemia before birth. The global distribution of the disorder correlates strongly with historical endemic regions of Malaria.

Genetics and molecular basis

The molecular foundation lies in the alpha-globin gene cluster on the short arm of Chromosome 16. Each individual normally inherits four functional alpha-globin genes, two from each parent on the homologous chromosomes. The most common cause worldwide is the deletion of one or more of these genes, with over 30 different deletion mutations identified. Non-deletional mutations, such as point mutations affecting the HBA2 gene, can also occur and sometimes lead to more severe clinical manifestations like Hemoglobin Constant Spring. The reduced production of alpha-globin chains leads to an excess of beta-globin chains in red blood cells, which form unstable tetramers like Hemoglobin H that precipitate and cause hemolytic anemia.

Classification and subtypes

The disorder is classified based on the number of functional alpha-globin genes affected. The silent carrier state involves the loss of a single gene and is typically asymptomatic. Alpha thalassemia trait, or alpha thalassemia minor, results from the loss of two genes and may cause mild microcytic anemia. Hemoglobin H disease is caused by the loss of three functional genes, leading to moderate to severe hemolytic anemia and requiring occasional medical intervention. The most severe form, Hb Bart's hydrops fetalis syndrome, occurs when all four alpha-globin genes are deleted, usually resulting in fatal hydrops fetalis unless aggressive intrauterine therapy is initiated, such as at the University of California, San Francisco Fetal Treatment Center.

Signs and symptoms

Clinical presentation is directly related to the subtype. The trait form may be asymptomatic or present with mild Anemia and microcytosis. Hemoglobin H disease often manifests with fatigue, Jaundice, Pallor, and Splenomegaly due to chronic hemolysis and extramedullary hematopoiesis. Patients are prone to Gallstones and episodes of worsening anemia triggered by infections or exposure to oxidative drugs. Hb Bart's hydrops fetalis causes severe fetal anemia leading to Congestive heart failure, massive edema, and Placental hypertrophy, and is often fatal in utero or shortly after birth without intervention.

Diagnosis

Diagnosis involves a combination of laboratory tests and clinical evaluation. Initial screening typically includes a Complete blood count showing microcytic, hypochromic red cells with a normal Ferritin level to rule out Iron deficiency anemia. Hemoglobin electrophoresis may reveal the presence of Hemoglobin H or Hb Bart's in more severe forms. Definitive diagnosis is achieved through Genetic testing, such as Multiplex ligation-dependent probe amplification or DNA sequencing, to identify specific deletions or mutations. Prenatal diagnosis via Chorionic villus sampling or Amniocentesis is offered in high-risk populations, often coordinated through institutions like the National Institutes of Health.

Management and treatment

Management is supportive and varies by severity. Individuals with the trait require no treatment. For Hemoglobin H disease, management includes avoidance of oxidative medications, supplementation with Folic acid, and timely treatment of infections. Severe anemia may necessitate occasional Blood transfusion. For transfusion-dependent patients, Iron chelation therapy with agents like Deferoxamine or Deferasirox is critical to prevent complications of Iron overload such as Cardiomyopathy and Diabetes mellitus. The only curative treatment is Allogeneic hematopoietic stem cell transplantation, a procedure with significant risk. For Hb Bart's hydrops fetalis, experimental in utero transfusions have been pioneered at centers like the Children's Hospital of Philadelphia.

Epidemiology

It is one of the most common single-gene disorders globally. Its high frequency is attributed to the heterozygote advantage against severe Malaria, leading to selective pressure in endemic regions. The highest carrier frequencies are found in populations from Southeast Asia, particularly in Thailand, Cambodia, and Laos, the Mediterranean Basin including Greece and Cyprus, the Middle East, and parts of Africa. In the United States, the prevalence is increased among individuals with ancestry from these regions, with significant communities in states like California and New York. Public health initiatives, such as those by the World Health Organization, focus on screening and genetic counseling in high-prevalence areas.

Category:Hematology Category:Genetic disorders